Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
CLEC20A, most accurately described as "long intergenic non-protein coding RNA 83 (LINC00083)," is a genomic locus annotated as a noncoding RNA with no proven protein product, biological function, or association with known molecular families such as C-type lectin receptors. While its name suggests membership in the C-type lectin domain family, there is no evidence CLEC20A encodes a membrane protein, receptor, or glycoprotein related to immune response, as is seen with CLEC12A or CLEC2A[3]. The present nomenclature and alternative names appear to be artifacts of genomic annotation and not an indication of molecular or functional classification, meaning CLEC20A should not be considered a classical molecular target or receptor. If your inquiry pertains to the characterized C-type lectin receptors (such as CLEC12A or CLEC2A), those are protein-coding genes involved in immune response and considered valid therapeutic targets[1][3]. CLEC20A/LINC00083 does not currently fit this description and is likely a misannotation or ambiguous synonym.
None
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on long intergenic non-protein coding RNA 83 (LINC00083).